Prevalence of platelet transfusion reactions before and after implementation of leukocyte-depleted platelet concentrates by filtration.
To determine the impact of platelet leukodepletion by filtration on the overall prevalence of reported transfusion reactions associated with platelet concentrates, we audited platelet transfusion reactions after infusion of platelet concentrates reported at University Hospitals of Cleveland over 6 months before (interval 1, July 1, 1989 to December 31, 1989) and after (interval 2, July 1, 1990 to December 31, 1990) implementation of the Pall PL 50 filter on our adult Hematology-Oncology inpatient unit (Division 60). Thirty-two (1.7%) of 1,901 random, pooled platelet transfusion events resulted in blood bank transfusion reaction workups in interval 1, compared to 90 (5.3%) of 1,704 in interval 2 (p < 0.001). The Division 60 service accounted for more of our hospital-wide platelet reactions after implementation of the filter in interval 2 (84%) than before filtration in interval 1 (42%), p = 0.002. The prevalence of reaction workups for Division 60 was 0.6% for interval 1, compared to 4.3% for interval 2 (p < 0.001). No differences were found between interval 1 and interval 2 for the rate of discontinuation of platelet transfusion (36 vs. 32%, p = 0.14), rate of premedication for platelet transfusion (72 vs. 65%, p = 0.6), percentage of direct antiglobulin test-positive reactions (17 vs. 5.4%, p = 0.09), percentage showing icteric/hemolyzed serum (15 vs. 4.4%, p = 0.09), or reactions believed to be due to red blood cell incompatibility (8.8 vs. 1.1%, p = 0.1).(ABSTRACT TRUNCATED AT 250 WORDS)
Goodnough
L T
LT
Department of Medicine, Case Western Reserve University, Cleveland, Ohio.
Riddell
J
J
Lazarus
H
H
Chafel
T L
TL
Prince
G
G
Hendrix
D
D
Yomtovian
R
R
D000017:ABO Blood-Group System / Q000276:immunology; D001788:Blood Grouping and Crossmatching; D005260:Female; D005374:Filtration; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D010976:Platelet Count; D017713:Platelet Transfusion / Q000009:adverse effects*; D015995:Prevalence
D000017:ABO Blood-Group System